Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940297 · ClinicalTrials.gov registry record · Phase 2
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06940297 is a Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 44 participants, roughly in line with the 47-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06940297, a Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Biopsy Procedure
- BIOLOGICAL Ciltacabtagene Autoleucel
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2031-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06940297
The ClinicalTrials.gov registry entry for NCT06940297 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 47-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06940297 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06940297 about?
NCT06940297 is a clinical study titled "Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma". This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous t...
What is the current status of trial NCT06940297?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-06-23. Estimated completion is 2031-08-15.
What conditions does trial NCT06940297 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Recurrent Multiple Myeloma.
What interventions are being tested in trial NCT06940297?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Biopsy Procedure (PROCEDURE), Ciltacabtagene Autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06940297?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940297 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
RECRUITING · Phase 2
-
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
RECRUITING · Phase 2
-
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.